Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients.
Niccolò RiccardiFilippo Del PuenteLucia TaramassoAntonio Di BiagioPublished in: Journal of the International Association of Providers of AIDS Care (2020)
Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor-based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus-infected patients. Thus, we performed a 24-week real-life observational study to assess efficacy and safety of switching from raltegravir plus etravirine to dolutegravir plus rilpivirine in 7 previously heavily treated patients. This simplification strategy reduced pill burden and preserved viral suppression in treatment-experienced patients with no major mutations to rilpivirine at historical genotyping.
Keyphrases
- hiv infected patients
- antiretroviral therapy
- human immunodeficiency virus
- hiv infected
- hiv positive
- hiv aids
- newly diagnosed
- sars cov
- end stage renal disease
- hepatitis c virus
- prognostic factors
- dna methylation
- clinical trial
- genome wide
- robot assisted
- peritoneal dialysis
- gene expression
- stem cells
- single cell
- study protocol
- combination therapy
- mesenchymal stem cells